Logo

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome

Share this

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome

Shots:

  • The approval is based on the ICONIC study as well as 5yrs. of data from supportive studies that evaluate Livmarli in 86 patients with ALGS
  • The results from the ICONIC study demonstrated a significant reduction in pruritus that was maintained through 4yrs.
  • Livmarli is the first FDA-approved therapy for patients aged ≥1yrs. & the company has received a rare pediatric disease priority review voucher. The therapy will now be accessible to patients with a prescription through MAP that provides insurance coverage- and access support along with financial support options for patients with Livmarl

­ | Ref: Mirum  | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions